Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.
Also called NCT02922036
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 300 participants
- Sponsor
- EBR Systems, Inc.
- Registry
-
NCT02922036
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, France, Germany, Italy, Netherlands, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT02922036. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-17 (actual); primary completion 2027-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
- Acronym
- SOLVE-CRT
- Condition
- Heart Failure
- Intervention (Device)
- WiSE System
- Lead sponsor
- EBR Systems, Inc.
Record details
- Record id
cardio:ct-nct02922036- Content hash
7af569f434fb876a26ce4153c6e8b4c704517e219aedf19e3101c50947bf28dc